The Efficacy Of The Wavelight Mydon Laser for Hair Removal And Treatment of Leg Veins

Determine The Efficacy Of The Wavelight Mydon Laser For Hair Removal And Treatment of Leg Veins

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00366964

Enrollment

Registered

2006-08-22

Start date

2004-10-31

Completion date

2006-04-30

Last updated

2015-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hair Removal, Leg Veins

Brief summary

This study is being done to compare the efficacy of an FDA cleared laser device with other similar systems in the market for the treatment of leg veins and hair removal in patients with darker skin type.

Detailed description

The specific aim of the study is to determine the efficacy of this FDA approved laser for hair removal and treatment of leg veins in female patients having darker skin types (Fitzpatrick Skin type III-VI) and compare it with the efficacy of other similar commercial units available in the U.S.

Interventions

DEVICELaser Treatment

The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.

DEVICEWave Light laser device for skin treatment

To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Female patients of Asian and darker skin type greater than or equal to 18 years of age. 2. Ability to give informed consent.

Exclusion criteria

1. Pregnancy. 2. Taking medications that are photosensitizing. 3. History of skin disease in the area to be treated over the last 6 months. 4. Ongoing cutaneous lupus erythematosus, morphea, alopecia areata, or severe folliculitis. 5. History of keloidal or hypertrophic scarring. 6. Have inadequate hair growth in the test area of axilla. 7. Have unrealistic expectations of the treatment. 8. Co-existing severe emotional, medical or surgical illness leading to the inability to meet the follow-up requirements.

Design outcomes

Primary

Measure	Time frame
Safety and efficacy of the treatment will determine the outcome.	6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026